ATE408410T1 - Kombinationstherapie zur behandlung von hepatitis b infektionen - Google Patents

Kombinationstherapie zur behandlung von hepatitis b infektionen

Info

Publication number: ATE408410T1
Authority: AT; Austria
Prior art keywords: hepatitis; combination; alternation; administering; directed
Prior art date: 1998-11-02

Application number

AT03077542T

Other languages

English (en)

Inventor

Phillip A Furman

George Painter

David Barry

Franck Rousseau

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-02

Filing date

1999-11-02

Publication date

2008-10-15

1999-11-02 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2008-10-15 Application granted granted Critical

2008-10-15 Publication of ATE408410T1 publication Critical patent/ATE408410T1/de

Links

238000002648 combination therapy Methods 0.000 title 1
208000006454 hepatitis Diseases 0.000 title 1
231100000283 hepatitis Toxicity 0.000 title 1
208000015181 infectious disease Diseases 0.000 title 1
208000002672 hepatitis B Diseases 0.000 abstract 5
WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 abstract 3
JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 abstract 2
RLAHNGKRJJEIJL-RFZPGFLSSA-N [(2r,4r)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CO[C@@H](CO)O1 RLAHNGKRJJEIJL-RFZPGFLSSA-N 0.000 abstract 2
229960001179 penciclovir Drugs 0.000 abstract 2
241000701076 Macacine alphaherpesvirus 1 Species 0.000 abstract 1
GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 abstract 1
229960004396 famciclovir Drugs 0.000 abstract 1
GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Plural Heterocyclic Compounds (AREA)

AT03077542T 1998-11-02 1999-11-02 Kombinationstherapie zur behandlung von hepatitis b infektionen ATE408410T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US10666498P	1998-11-02	1998-11-02

Publications (1)

Publication Number	Publication Date
ATE408410T1 true ATE408410T1 (de)	2008-10-15

Family

ID=22312611

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT99961553T ATE287268T1 (de)	1998-11-02	1999-11-02	Kombinationstherapie zur behandlung von hepatitis b infektionen
AT03077543T ATE457734T1 (de)	1998-11-02	1999-11-02	Kombinationstherapie zur behandlung von hepatitis b infektionen
AT03077542T ATE408410T1 (de)	1998-11-02	1999-11-02	Kombinationstherapie zur behandlung von hepatitis b infektionen

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AT99961553T ATE287268T1 (de)	1998-11-02	1999-11-02	Kombinationstherapie zur behandlung von hepatitis b infektionen
AT03077543T ATE457734T1 (de)	1998-11-02	1999-11-02	Kombinationstherapie zur behandlung von hepatitis b infektionen

Country Status (15)

Country	Link
US (3)	US6528515B1 (de)
EP (3)	EP1380303B1 (de)
JP (2)	JP2002528508A (de)
KR (1)	KR100632520B1 (de)
CN (3)	CN1173705C (de)
AT (3)	ATE287268T1 (de)
AU (1)	AU1810600A (de)
CY (2)	CY1108635T1 (de)
DE (3)	DE69939604D1 (de)
DK (2)	DK1380303T3 (de)
ES (3)	ES2237189T3 (de)
ID (1)	ID29471A (de)
IL (3)	IL142910A0 (de)
PT (2)	PT1380303E (de)
WO (1)	WO2000025797A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2237189T3 (es) *	1998-11-02	2005-07-16	Gilead Sciences, Inc.	Terapia de combinacion para tratar virus de la hepatitis b.
ATE468123T1 (de) *	2002-06-19	2010-06-15	Fideline	Beruhigende vogel-pheromone zur verminderung von stress, angst und aggressivität
SG165996A1 (en) *	2002-07-15	2010-11-29	Gilead Sciences Inc	Combination therapies with l-fmau for the treatment of hepatitis b virus infection
SI1583542T1 (sl) *	2003-01-14	2008-12-31	Gilead Sciences Inc	Sestavki in postopki za kombinacijsko antivirusnoterapijo
TWI375560B (en)	2005-06-13	2012-11-01	Gilead Sciences Inc	Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh)	2005-06-13	2015-02-01	Bristol Myers Squibb & Gilead Sciences Llc	單一式藥學劑量型
WO2011145808A2 (ko) *	2010-05-18	2011-11-24	부광약품 주식회사	클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
KR20100127180A (ko) *	2009-05-25	2010-12-03	부광약품 주식회사	클레부딘 및 아데포비어 디피복실을 함유하는 만성 ｂ형 간염 치료용 조성물
BR112013014485B1 (pt)	2010-12-10	2021-03-30	Sigmapharm Laboratories, Llc	Composições farmacêuticas compreendendo pró-fármacos análogos de nucleotídeos de fosfonato ativos por via oral e sistema de embalagem de recipiente/fechamento contendo as ditas composições
JP6779232B2 (ja) *	2015-05-08	2020-11-04	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ウイルス感染の治療又は予防のための新規オキサチオランカルボン酸と誘導体
CN105943547B (zh) *	2016-05-23	2018-01-19	北京慧宝源生物技术股份有限公司	抗hbv的药物组合物及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5684153A (en)	1984-08-16	1997-11-04	Beecham Group Plc	Process for the preparation of purine derivatives
EP0141927B1 (de) *	1983-08-18	1991-10-30	Beecham Group Plc	Antivirale Guanin-Derivate
US5223263A (en)	1988-07-07	1993-06-29	Vical, Inc.	Liponucleotide-containing liposomes
CS264222B1 (en)	1986-07-18	1989-06-13	Holy Antonin	N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
EP0380558A4 (en)	1987-09-22	1991-07-31	The Regents Of The University Of California	Liposomal nucleoside analogues for treating aids
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8904855D0 (en) *	1989-03-03	1989-04-12	Beecham Group Plc	Pharmaceutical treatment
US5411947A (en)	1989-06-28	1995-05-02	Vestar, Inc.	Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5194654A (en)	1989-11-22	1993-03-16	Vical, Inc.	Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
US5463092A (en)	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5827727A (en)	1990-02-01	1998-10-27	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
US5700937A (en)	1990-02-01	1997-12-23	Emory University	Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5914331A (en)	1990-02-01	1999-06-22	Emory University	Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5204466A (en)	1990-02-01	1993-04-20	Emory University	Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
WO1991016920A1 (en)	1990-05-07	1991-11-14	Vical, Inc.	Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
JPH05507279A (ja)	1990-05-29	1993-10-21	ネクススター・ファーマシューティカルズ・インコーポレイテッド	グリセロールジ―およびトリホスフェート誘導体の合成
EP0533833B1 (de)	1990-06-13	1995-12-20	GLAZIER, Arnold	Phosphorylierte prodrugs
US5674869A (en) *	1990-07-07	1997-10-07	Beecham Group Plc	Pharmaceutical treatment
US5674849A (en)	1990-10-24	1997-10-07	Allelix Biopharmaceuticals Inc.	Anti-viral compositions
US5543389A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization	Covalent polar lipid-peptide conjugates for use in salves
US5543390A (en)	1990-11-01	1996-08-06	State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University	Covalent microparticle-drug conjugates for biological targeting
US5149794A (en)	1990-11-01	1992-09-22	State Of Oregon	Covalent lipid-drug conjugates for drug targeting
US5256641A (en)	1990-11-01	1993-10-26	State Of Oregon	Covalent polar lipid-peptide conjugates for immunological targeting
US5925643A (en)	1990-12-05	1999-07-20	Emory University	Enantiomerically pure β-D-dioxolane-nucleosides
US5444063A (en)	1990-12-05	1995-08-22	Emory University	Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en)	1990-12-05	1993-01-12	University Of Georgia Research Foundation, Inc.	Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
IL100502A (en)	1991-01-03	1995-12-08	Iaf Biochem Int	PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
GB9104740D0 (en)	1991-03-06	1991-04-17	Wellcome Found	Antiviral nucleoside combination
WO1992018517A1 (en)	1991-04-17	1992-10-29	Yale University	Method of treating or preventing hepatitis b virus
GB9110874D0 (en)	1991-05-20	1991-07-10	Iaf Biochem Int	Medicaments
AU668873B2 (en)	1991-07-12	1996-05-23	Chimerix, Inc.	Antiviral liponucleosides: treatment of hepatitis B
US5554728A (en)	1991-07-23	1996-09-10	Nexstar Pharmaceuticals, Inc.	Lipid conjugates of therapeutic peptides and protease inhibitors
GB9116601D0 (en)	1991-08-01	1991-09-18	Iaf Biochem Int	1,3-oxathiolane nucleoside analogues
US6177435B1 (en)	1992-05-13	2001-01-23	Glaxo Wellcome Inc.	Therapeutic combinations
AU701574B2 (en)	1993-05-12	1999-02-04	Karl Y. Hostetler	Acyclovir derivatives for topical use
US5587362A (en)	1994-01-28	1996-12-24	Univ. Of Ga Research Foundation	L-nucleosides
US5696277A (en)	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
US5703058A (en) *	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5808040A (en)	1995-01-30	1998-09-15	Yale University	L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US5869461A (en)	1995-03-16	1999-02-09	Yale University	Reducing toxicity of L-nucleosides with D-nucleosides
AU5127098A (en)	1996-11-29	1998-06-22	Smithkline Beecham Plc	Use of a combination of penciclovir and alpha-interferon in the manufacture of a medicament for the treatment of hepatitis
DE69823984T2 (de) *	1997-03-19	2005-05-12	University Of Georgia Research Foundation, Inc.	Synthese, anti-hiv- und anti-hepatitis-b-virus-aktivitäten von 1,3-oxaselenolannukleosiden
ES2237189T3 (es) *	1998-11-02	2005-07-16	Gilead Sciences, Inc.	Terapia de combinacion para tratar virus de la hepatitis b.

1999
- 1999-11-02 ES ES99961553T patent/ES2237189T3/es not_active Expired - Lifetime
- 1999-11-02 KR KR1020017005515A patent/KR100632520B1/ko not_active Expired - Fee Related
- 1999-11-02 ES ES03077542T patent/ES2314157T3/es not_active Expired - Lifetime
- 1999-11-02 PT PT03077542T patent/PT1380303E/pt unknown
- 1999-11-02 DE DE69939604T patent/DE69939604D1/de not_active Expired - Lifetime
- 1999-11-02 ES ES03077543T patent/ES2338642T3/es not_active Expired - Lifetime
- 1999-11-02 US US09/432,247 patent/US6528515B1/en not_active Expired - Lifetime
- 1999-11-02 DE DE69923338T patent/DE69923338T2/de not_active Expired - Lifetime
- 1999-11-02 AT AT99961553T patent/ATE287268T1/de not_active IP Right Cessation
- 1999-11-02 AU AU18106/00A patent/AU1810600A/en not_active Abandoned
- 1999-11-02 JP JP2000579237A patent/JP2002528508A/ja not_active Ceased
- 1999-11-02 CN CNB99814147XA patent/CN1173705C/zh not_active Expired - Fee Related
- 1999-11-02 IL IL14291099A patent/IL142910A0/xx unknown
- 1999-11-02 AT AT03077543T patent/ATE457734T1/de active
- 1999-11-02 DK DK03077542T patent/DK1380303T3/da active
- 1999-11-02 EP EP03077542A patent/EP1380303B1/de not_active Expired - Lifetime
- 1999-11-02 DK DK03077543.1T patent/DK1382343T3/da active
- 1999-11-02 ID IDW00200101179A patent/ID29471A/id unknown
- 1999-11-02 EP EP99961553A patent/EP1124562B1/de not_active Expired - Lifetime
- 1999-11-02 EP EP03077543A patent/EP1382343B1/de not_active Expired - Lifetime
- 1999-11-02 DE DE69942042T patent/DE69942042D1/de not_active Expired - Lifetime
- 1999-11-02 PT PT03077543T patent/PT1382343E/pt unknown
- 1999-11-02 WO PCT/US1999/025673 patent/WO2000025797A1/en not_active Ceased
- 1999-11-02 AT AT03077542T patent/ATE408410T1/de active
- 1999-11-02 CN CNA2006100999317A patent/CN1891221A/zh active Pending
- 1999-11-02 CN CNA2004100771301A patent/CN1666742A/zh active Pending
2001
- 2001-05-01 IL IL142910A patent/IL142910A/en not_active IP Right Cessation
2003
- 2003-02-25 US US10/374,363 patent/US7572800B2/en not_active Expired - Fee Related
2008
- 2008-07-31 IL IL193148A patent/IL193148A/en not_active IP Right Cessation
- 2008-12-10 CY CY20081101433T patent/CY1108635T1/el unknown
2009
- 2009-06-12 US US12/483,800 patent/US20090247487A1/en not_active Abandoned
2010
- 2010-04-30 CY CY20101100385T patent/CY1110629T1/el unknown
- 2010-11-11 JP JP2010252915A patent/JP2011079840A/ja active Pending

Also Published As

Publication number	Publication date
EP1380303B1 (de)	2008-09-17
US20030158150A1 (en)	2003-08-21
ES2338642T3 (es)	2010-05-11
DK1382343T3 (da)	2010-04-26
EP1382343A1 (de)	2004-01-21
ES2314157T3 (es)	2009-03-16
JP2002528508A (ja)	2002-09-03
CY1108635T1 (el)	2014-04-09
EP1382343B1 (de)	2010-02-17
IL193148A (en)	2011-09-27
US6528515B1 (en)	2003-03-04
HK1062146A1 (en)	2004-10-21
EP1124562A1 (de)	2001-08-22
US20090247487A1 (en)	2009-10-01
CN1666742A (zh)	2005-09-14
DE69939604D1 (de)	2008-10-30
CN1329497A (zh)	2002-01-02
DE69942042D1 (de)	2010-04-01
AU1810600A (en)	2000-05-22
ATE287268T1 (de)	2005-02-15
DE69923338D1 (de)	2005-02-24
IL142910A0 (en)	2002-04-21
DK1380303T3 (da)	2008-12-01
ID29471A (id)	2001-08-30
CY1110629T1 (el)	2015-04-29
CN1173705C (zh)	2004-11-03
PT1382343E (pt)	2010-03-10
IL142910A (en)	2009-06-15
KR20010082282A (ko)	2001-08-29
CN1891221A (zh)	2007-01-10
ES2237189T3 (es)	2005-07-16
IL193148A0 (en)	2009-02-11
PT1380303E (pt)	2008-11-03
KR100632520B1 (ko)	2006-10-09
WO2000025797A1 (en)	2000-05-11
EP1380303A1 (de)	2004-01-14
DE69923338T2 (de)	2006-04-06
US7572800B2 (en)	2009-08-11
JP2011079840A (ja)	2011-04-21
ATE457734T1 (de)	2010-03-15
EP1124562B1 (de)	2005-01-19

Legal Events

Date

Code

Title

Description

2009-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1380303

Country of ref document: EP

Publication	Publication Date	Title
CY1110629T1 (el)	2015-04-29	Πολυθεραπεια για θεραπευτικη αγωγη ιου ηπατιτιδας β
DE69233631D1 (de)	2006-07-27	1,3-Oxathiolane zur Behandlung von Hepatitis
DE69535758D1 (de)	2008-07-03	Lipid-analoge zur behandlung von viralen infektionen
DE69523350D1 (de)	2001-11-29	Behandlung von hyperproliferativen Gefässerkrankungen
ATE342728T1 (de)	2006-11-15	Zubereitung zur behandlung von einer neurologischen erkrankung
EA200600582A1 (ru)	2006-08-25	Способы и композиции для лечения вирусного гепатита с
DE60136620D1 (de)	2009-01-02	3 oder 2 hydroxymethyl substituierte nucleoside derivate und ihre verwendung zur behandlung von virusinfektionen
ATE275406T1 (de)	2004-09-15	Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
PL296460A1 (en)	1993-12-13	Method of obtaining a trombine preparation effectively protected against viruses
DE60039729D1 (de)	2008-09-11	N-(8,8,8-Trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol zur Behandlung von Hepatitis-Virus-Infektionen
DE69116380D1 (de)	1996-02-22	Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
ATE235495T1 (de)	2003-04-15	8-arylalkyl- und 8-arylheteroalkyl-5, 11-dihydro- 6h-dipyrido-(3,2-b:2', 3'-e)(1,4)diazepine und ihre verwendung zur vorbeugung oder behandlung von hiv-infektion
DE60237721D1 (de)	2010-10-28	Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
NO994330D0 (no)	1999-09-06	Metode for behandling av en tumor
DE60123042D1 (de)	2006-10-26	L-fmau zur behandlung von hepatitis-delta-virus-infizierung
ATE281173T1 (de)	2004-11-15	Behandlung einer virusinfektion bei schweinen
ATE255417T1 (de)	2003-12-15	Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
DE69210737D1 (de)	1996-06-20	Verwendung von L-2-Oxothiazolidine-4-Carboxylate zur Herstellung eines Arzneimittels zur Behandlung von latenten HIV-Infektionen
DE69006187D1 (de)	1994-03-03	Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
ATE74755T1 (de)	1992-05-15	Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-am no-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
EA200001065A1 (ru)	2001-06-25	Применение фосфорорганических соединений для терапевтического и профилактического лечения инфекций